Multi-modality cohort study demonstrates enhanced survival risk stratification in gastric cancer, highlighting a new biomarker for therapy guidance.
Deep learning-derived CTBC metrics, especially VAT/SAT ratio, enhance prognostic stratification beyond TNM staging in locally advanced gastric cancer. This ratio captures a systemic and tumor-level immunometabolic phenotype marked by mitochondrial dysfunction and immune suppression. Our findings highlight VAT/SAT as a noninvasive, clinically actionable biomarker to guide personalized therapy and risk-adapted algorithm in gastric cancer management.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: